IN2015DN01496A - - Google Patents

Download PDF

Info

Publication number
IN2015DN01496A
IN2015DN01496A IN1496DEN2015A IN2015DN01496A IN 2015DN01496 A IN2015DN01496 A IN 2015DN01496A IN 1496DEN2015 A IN1496DEN2015 A IN 1496DEN2015A IN 2015DN01496 A IN2015DN01496 A IN 2015DN01496A
Authority
IN
India
Prior art keywords
cancer
wilfordii
organic solvent
treatment
chemotherapeutic
Prior art date
Application number
Inventor
Moses Sing Sum Chow
Ying Huang
Jinghua Jeffrey Wang
Ranadheer Ravula
zhi jun Wang
Original Assignee
Univ Western Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Western Health Sciences filed Critical Univ Western Health Sciences
Publication of IN2015DN01496A publication Critical patent/IN2015DN01496A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides extracts and compositions derived from Tripterygium wilfordii for overcoming drug resistance in cancer therapy. This invention relates to organic solvent extracts of T. wilfordii and their use in cancer treatment, particularly in the treatment of cancers which have exhibited resistance to treatment by chemotherapeutic drugs. Methods of treating a cancer are disclosed. The method administers to a patient in need thereof a combination of (a) an organic solvent extract of T. wilfordii and (b) a chemotherapeutic drug. The organic solvent extract of T. wilfordii (a) and chemotherapeutic drug (b) are administered in a combined amount effective to treat the cancer. The cancer being treated is at least in part resistant to treatment by the chemotherapeutic drug (b) alone. Also disclosed are chemotherapeutic compositions comprising a combination of (a) an organic solvent extract of T. wilfordii and (b) a chemotherapeutic drug, wherein (a) and (b) are administered in a combined amount effective to treat the cancer; and a pharmaceutically acceptable carrier.
IN1496DEN2015 2012-08-19 2013-08-19 IN2015DN01496A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261684792P 2012-08-19 2012-08-19
PCT/US2013/055602 WO2014031543A1 (en) 2012-08-19 2013-08-19 Tripterygium wilfordii extracts to overcome chemotherapy resistance

Publications (1)

Publication Number Publication Date
IN2015DN01496A true IN2015DN01496A (en) 2015-07-03

Family

ID=50150329

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1496DEN2015 IN2015DN01496A (en) 2012-08-19 2013-08-19

Country Status (9)

Country Link
US (1) US10149876B2 (en)
EP (1) EP2888011A4 (en)
JP (1) JP6367801B2 (en)
CN (1) CN104797296B (en)
AU (2) AU2013306058A1 (en)
CA (1) CA2880575C (en)
HK (2) HK1212270A1 (en)
IN (1) IN2015DN01496A (en)
WO (1) WO2014031543A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6529138B2 (en) * 2013-09-13 2019-06-12 ウェスタン ユニバーシティ オブ ヘルス サイエンス Use of wilforlide A to overcome chemoresistance
CN111909119B (en) * 2020-08-25 2023-06-16 上海诗丹德标准技术服务有限公司 Tripterygium wilfordii source compound and application and preparation method thereof, pharmaceutical composition and pesticide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013627A1 (en) * 1990-03-14 1991-09-19 The Board Of Regents, The University Of Texas System Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
JP2004075888A (en) * 2002-08-20 2004-03-11 Konica Minolta Holdings Inc Fluorescent coating material or fluorescent ink and fluorescent image, and its formation method
JPWO2004075888A1 (en) 2003-02-27 2006-06-01 輝夫 西田 Corneal ulcer treatment
CN102443039B (en) * 2010-10-14 2013-11-13 中国科学院上海药物研究所 N-substituted amino phenyl-14 beta-(aminomethyl) triptodiolide derivative and preparation method and application thereof

Also Published As

Publication number Publication date
CA2880575C (en) 2023-07-11
AU2018200709B2 (en) 2019-10-24
CN104797296B (en) 2019-12-17
CN104797296A (en) 2015-07-22
AU2018200709A1 (en) 2018-02-22
WO2014031543A1 (en) 2014-02-27
AU2013306058A1 (en) 2015-02-19
EP2888011A1 (en) 2015-07-01
HK1212270A1 (en) 2016-06-10
HK1211888A1 (en) 2016-06-03
EP2888011A4 (en) 2016-01-27
CA2880575A1 (en) 2014-02-27
US10149876B2 (en) 2018-12-11
JP2015529664A (en) 2015-10-08
JP6367801B2 (en) 2018-08-01
US20150238553A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
MX2017016491A (en) Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy.
MX2019012462A (en) Combination therapy.
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
MX2019010601A (en) Combination therapy for treating cancer.
MY166014A (en) Combination therapy methods for treating proliferative diseases
WO2016025635A3 (en) Combination therapy for treating cancer
MX2016007351A (en) Combination therapy for treating cancer.
PH12014501560A1 (en) Carbamate compounds and of making and using same
WO2007084670A3 (en) Specific therapy using integrin ligands for treating cancer
PH12016502354A1 (en) Pharmaceutical composition
WO2008087025A3 (en) Specific therapy and medicament using integrin ligands for treating cancer
RU2016112608A (en) TREATMENT OF CANCER BY THE COMBINATION OF PLINABULIN AND TAXAN
MX2017017138A (en) Targeted conjugates of ksp inhibitors.
WO2011017534A3 (en) Treatment of prostate cancer
MX2015010791A (en) Methods of treating cancer and preventing drug resistance.
WO2016043874A3 (en) Combination therapy for treating cancer
ZA202302155B (en) Interferon-based cancer treatment method and pharmaceutical composition
MX2015015434A (en) Targeting corroles for tumor toxicity and mri.
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
EA201691570A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING DIAMINO-HETEROCYCLIC CARBOXAMIDE COMPOUND AS AN ACTIVE INGREDIENT
MX2019002121A (en) Combination therapy for the treatment of pancreatic cancer.
IN2015DN01496A (en)
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
WO2010057596A3 (en) New therapy and medicament using integrin ligands for treating cancer